Published in final edited form as:

Biochem Biophys Res Commun. 2008 October 10; 375(1): 1–5. doi:10.1016/j.bbrc.2008.07.055.

Expression of *p14^{ARF}*, *MDM2* and *MDM4* in human retinoblastoma

Ying Guo¹, Sanja Pajovic¹, and Brenda L Gallie^{1,2,3,4}

¹Division of Applied Molecular Oncology, Ontario Cancer Institute/Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada

²Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada

³Department of Molecular & Medical Genetics, University of Toronto, Toronto, Ontario, Canada

⁴Department of Ophthalmology, University of Toronto, Toronto, Ontario, Canada

Abstract

It is still not clear whether the p53 pathway is altered in retinoblastoma development. We assessed the expression of the p53 pathway genes *p14^{ARF}*, *mouse double minute 2 (MDM2)* and *mouse double minute 4 (MDM4)* in human retinoblastoma compared to normal retina. Primary human retinoblastomas, retinoblastoma cell lines and normal retinas were assessed for *p14^{ARF}* and *MDM4* mRNA by quantitative RT-PCR. *p14^{ARF}*, *MDM2* and *MDM4* protein were measured by immunoblot and immunohistochemistry. Compared to retina, *p14^{ARF}* mRNA expression was notably increased in retinoblastoma but *p14^{ARF}* protein was undetectable. *MDM2* and *MDM4* proteins were expressed in 22/22 retinoblastomas. *MDM2* was expressed in 3/10 retinas tested, and *MDM4* in 10/10 retinas. The expression level of *MDM2* protein in retinoblastomas and retina was comparable, while *MDM4* protein was overexpressed in one retinoblastoma cell line Y79 and two primary retinoblastomas. We observe that overexpression of *MDM2* and *MDM4* is not a necessary step in retinoblastoma development. However, loss of detectable *p14^{ARF}* protein and resultant lack of functional inactivation of these p53 inhibitors may contribute to retinoblastoma development by constitutive inhibition of p53.

Keywords

Retinoblastoma; *p14^{ARF}*; *MDM2*; *MDM4*

p14^{ARF}(human)/*p19^{ARF}* (mouse) is an important tumor suppressor and its expression is lost in many cancers [1–4]. *p19^{ARF}* null mouse embryo fibroblasts can be transformed by a single oncogene such as *c-Myc* or *RasV12*, and *p19^{ARF}*-null mice spontaneously and rapidly develop different types of cancer in their first year of life [5]. Although the mechanism is still not very clear, in general *p14^{ARF}* prevents tumor formation through the *MDM2*-p53 tumor surveillance pathway [6,7]. In cells with an intact *p14^{ARF}*-*MDM2*-p53 pathway, aberrant mitogenic signals and inactivation of the retinoblastoma tumor-suppressor gene (*RBI*) induce expression of *p14^{ARF}* [8–12], which in turn antagonizes the ubiquitin ligase activity of *MDM2*, stabilizes p53 and triggers p53-dependent G1 phase arrest or apoptosis [13–16]. Abrogation of the

Correspondence to: Brenda L. Gallie, Division of Applied Molecular Oncology, Ontario Cancer Institute/Princess Margaret Hospital, University Health Network, Room 8-415, 610 University Avenue, Toronto, ON M5G 2M9. Phone: +1-416-946-2324; Fax: +1-416-946-4619; E-mail: gallie@atglobal.net.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

p14^{ARF}-MDM2-p53 tumor surveillance pathway allows mutant cells to bypass apoptosis and proliferate continuously, thereby increasing susceptibility to cancer. Although inactivation of this tumor surveillance pathway, either by loss of p14^{ARF} or p53, or by overexpression of *MDM2*, has been reported in various tumor types [2], it is unclear whether these genes are involved in retinoblastoma development. It has been shown previously that p53 gene and protein remain normal in retinoblastoma [17,18]. However, a recent report showed that *MDM2* and a similar gene *MDM4* [19] were amplified frequently in retinoblastoma, and that the consequent overexpression of *MDM2* and *MDM4* blocked the function of p53 in retinoblastoma cells [12]. These findings suggested that at least in some retinoblastoma, amplification and overexpression of *MDM2* or *MDM4* could compromise p53 function, which may contribute to tumorigenesis.

To elucidate their roles in retinoblastoma development, we compared expression of p14^{ARF}, *MDM2* and *MDM4* in normal retina and retinoblastoma. In contrast to what was previously reported [12], we found that although p14^{ARF} message was notably increased in retinoblastoma compared to retina, p14^{ARF} protein was undetectable. We also show that MDM2 and MDM4 were expressed in all retinoblastoma samples tested. MDM2 protein was expressed at levels comparable to human retina, while MDM4 protein was overexpressed in one retinoblastoma cell line and two primary retinoblastomas.

Materials and Methods

Specimen Collection

Control normal human retinas (Table 1) were obtained from the enucleated eyes of cornea donors in the Eye Bank of Canada, with the University Health Network Research Ethics Board (REB) approval for anonymous use of discarded specimens. Retinoblastoma tumor samples (Table 1) were obtained from eyes removed as part of therapy with approval of REB of the Hospital for Sick Children and the University Health Network. Research studies were performed only after all clinical tests were complete. Retinoblastoma cells lines Y79 [20] and WERI-RB1 [21] were obtained from their originators; cervical carcinoma cell lines C33A and Hela were purchased from American Type Culture Collection (Manassas, VA, USA).

Quantitative RT-PCR

Total RNA was prepared using TRIzol reagent (Invitrogen, Burlington, ON, Canada) and cDNA was synthesized using SuperScript II reverse transcriptase (Invitrogen) and random primers. Gene specific primers p14^{ARF} (product ID:Hs99999_ml), *MDM4* (product ID:SRGHs00159092_ml) and *TBP* (product ID:Hs99999910_ml) were designed using Primer Express software (Applied Biosystems, Foster City, CA). Quantitative RT-PCR was performed in triplicate using ABI 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA). The data were normalized to *TBP* expression and analyzed by SDS2.1 software (Applied Biosystems, Foster City, CA).

Immunoblot

Cells were lysed with 1x whole cell extraction buffer (20 mM Hepes, PH 7.4, 100 mM KCl, 1 mM MgCl₂, 0.1 mM EDTA, 7% glycerol, 1 mM NaF, 0.2mM DTT, 0.2mM PMSF, 1% NP40, 5 µg /ml aprotinin and leupeptin). Samples (30 µg protein per lane) were separated by electrophoresis on 10–20% gradient SDS–PAGE gels (Bio-Rad, Hercules, CA) and were transferred to Immobilon polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA). Proteins were detected using anti-MDM2 mouse monoclonal antibody (1:200, Calbiochem, San Diego, CA), anti-MDM4 rabbit polyclonal antibody (1:500, Bethyl, TX) and anti-ARF rabbit polyclonal antibody(1:200, Abcam, Cambridge, MA), followed by either goat anti-mouse IgG or goat anti-rabbit IgG-horseradish peroxidase conjugated secondary antibody

(1:10,000, Santa Cruz Biotechnology, Santa Cruz, CA). Proteins were visualized using enhanced chemiluminescence reagents (Amersham, Little Chalfont, United Kingdom). β -tubulin mouse monoclonal antibody was used as a loading control. (1:1,000, Sigma Chemical Co., St. Louis, MO).

Immunohistochemistry

Formaldehyde-fixed, paraffin-embedded (FFPE) sections (7 μ m) of human retinas and retinoblastomas were deparaffinized and rehydrated followed by antigen retrieval by heating. Hela cells, used as positive control for p14^{ARF} protein were fixed with 4% PFA. Specimens were blocked with 10% commercial blocking solution (DAKO, Mississauga, ON, Canada). Sections were stained for 1 hour with anti-p14^{ARF} rabbit polyclonal antibody (Abcam, Cambridge, MA), followed by 1-hour incubation with biotinylated anti-rabbit immunoglobulin (Santa Cruz Biotechnology, Santa Cruz, CA) and streptavidin-conjugated Alexa 594 (Invitrogen, Burlington, Ontario). Images were captured using a Coolsnap camera attached to a Leica DMLB microscope and processed using Photoshop 7.0 software.

Results

p14^{ARF} mRNA is markedly elevated in retinoblastoma

To determine if p14^{ARF} expression was induced in retinoblastoma, we first measured p14^{ARF} mRNA expression by quantitative RT-PCR in 6 normal retinas, 2 retinoblastoma cell lines and 14 retinoblastoma primary tumors. Compared to normal retinas, all primary retinoblastomas and retinoblastoma cell lines displayed a prominent increase in p14^{ARF} mRNA (Fig. 1A and data not shown). Levels of p14^{ARF} mRNA in primary retinoblastomas were 500–1000 fold higher than in normal retinas (Fig. 1A). Surprisingly, p14^{ARF} mRNA expression in retinoblastoma cell lines was lower than primary retinoblastomas, but was still approximately 50-fold higher than in normal retinas.

p14^{ARF} protein is undetectable in retinoblastoma

The striking elevation of p14^{ARF} mRNA in retinoblastoma compared to retina prompted us to measure p14^{ARF} protein levels. Protein lysates from 20 primary retinoblastomas and 2 retinoblastoma cell lines were tested for expression of p14^{ARF} protein expression by immunoblot, and 6 retinoblastomas were immunostained with p14^{ARF} antibody. In contrast to the mRNA results, by both immunoblot and immunohistochemistry, p14^{ARF} protein was undetectable in both primary retinoblastomas and retinoblastoma cell lines, similar to normal retinas (Figure 1B and data not shown). As expected, we detected p14^{ARF} protein by immunoblot and immunofluorescence in the positive controls C33A (Figure 1B and C) and Hela cell lines (data not shown).

MDM2 and MDM4 are expressed in retinoblastoma

We examined the expression of MDM2 and MDM4, two inhibitors of p53 activity. *MDM4* mRNA was detected in all (100%) of normal retinas (6/6), retinoblastoma cell lines (2/2) and primary retinoblastomas (14/14) tested (Fig. 2A and data not shown). MDM4 protein was detected in 100% of primary retinoblastomas (20/20) and retinoblastoma cell lines (2/2) tested. For most retinoblastomas, MDM4 protein was expressed at levels comparable to unaffected retinas, but was overexpressed in one retinoblastoma cell line Y79 and two primary retinoblastomas (Fig. 2B and data not shown). MDM2 protein was detected in 30% (3/10) of human retinas and 100% of retinoblastomas (20/20) and retinoblastoma cell lines (2/2) (Fig. 3 and data not shown). MDM2 protein expression levels in retinoblastomas and RB cell lines were not elevated compared to normal retinas.

Discussion

It should be noted that in the current study we compared expression of p14^{ARF}, MDM2, and MDM4 in normal retinal tissues, tumor samples (both are *ex vivo*) and retinoblastoma cell lines (*in vitro*), therefore it is possible that some results might reflect these various origins of tissue, rather than the true biology. As well, the cell or origin of retinoblastoma is not known, and postnatal human retina is only an approximation.

Though loss of *RBI* function is regarded as the first pivotal step in retinoblastoma development, numerous studies have suggested that additional genetic alterations are required for full malignant transformation of retina to retinoblastoma [22,23]. In many tissues, *RBI* loss induces high p14^{ARF} expression [8,24], which in turn inhibits MDM2 and activates p53 dependent cell arrest and/or apoptosis [2,11]. Earlier studies suggest that *p53* gene and protein remained normal in retinoblastoma [17,18]. Therefore, it is interesting to speculate that the other members of p14^{ARF}-MDM2-p53 tumor surveillance pathway could be altered in retinoblastoma to allow these *RBI* mutant cells to proliferate unchecked.

In one cohort of samples, levels of p14^{ARF} mRNA in retinoblastoma were dramatically higher than in normal retina [12]. Consistent with these results, we also found marked elevation of p14^{ARF} mRNA in retinoblastomas. However, this high p14^{ARF} mRNA expression is not matched by protein, which was undetectable in retinoblastomas. The increase of p14^{ARF} mRNA in retinoblastomas may reflect an intact initial p14^{ARF} response to *RBI* loss in these tumor cells. The discrepancy between mRNA and protein expression of p14^{ARF} suggests that a post-transcriptional mechanism actively blocks p14^{ARF} function in retinoblastoma. Two mechanisms have been identified so far for the loss of p14^{ARF} expression in a variety of tumors: methylation of a CpG island in the *ARF* promoter and biallelic deletion of the entire *ARF* locus [25–28]. The post-transcriptional silencing of p14^{ARF} in retinoblastoma as reported here adds another novel mechanism for the loss of p14^{ARF} expression in tumors. The molecular details of this novel mechanism and its role in development of retinoblastoma and other tumors need further study.

MDM2 is a well-studied oncogene that is able to inactivate p53 by proteasome-dependent degradation [29,30]. p14^{ARF} segregates MDM2 from p53 and antagonizes the E3 ubiquitin protein ligase activity of MDM2, thus blocking inactivation of p53 [6,13–16]. *MDM2* is overexpressed in 5–10% of human tumors, potentially resulting in disruption the p14^{ARF}-MDM2-p53 pathway [2,11]. We show that the majority of normal retinas (70%) did not express MDM2, but MDM2 was expressed in all the retinoblastoma samples and cell lines tested. The absence of detectable p14^{ARF} protein in our samples suggests that MDM2 protein in retinoblastoma may be unsuppressed and thereby constitutively block p53 tumor surveillance and promote retinoblastoma development. This hypothesis is supported by recent studies showing that nutlin, a small molecule inhibitor of MDM2, can reactivate p53 function and induce cell death of retinoblastoma cells [12,31].

MDM4 was identified as a p53 binding protein with similar structure to MDM2 [19,32] that can antagonize the transcriptional activity of p53 [19]. Amplification and overexpression of *MDM4* has been detected in some primary tumors and cell lines, especially in tumors with wild type *p53* [33,34]. Therefore, *MDM4* may contribute to tumorigenesis as an oncogene. One study showed amplification of *MDM4* in 3/7 fresh and in 13/49 paraffin-embedded retinoblastoma tumors, however overexpression of MDM4 protein could only be detected in some primary retinoblastomas [12]. We found the expression levels of MDM4 protein in most retinoblastoma and normal retinas were similar. Furthermore in our cohort of retinoblastoma samples we detected gain of MDM4 in 2/4 samples and only in combination with the more highly and frequently gained/amplified oncogene *KIF14*, located close to MDM4 on 1q [35].

To what extent *MDM4* is amplified and overexpressed in retinoblastoma and whether *MDM4* plays a major role in retinoblastoma development needs further study.

In summary, p14^{ARF} was overexpressed at mRNA level but the protein remained undetectable in retinoblastomas compared with normal retinas. *MDM2* was expressed in all retinoblastomas but only in 3 of 10 normal retinas. *MDM4* was expressed in both retinoblastomas and normal retinas and for most retinoblastomas was not overexpressed. Our findings suggest that post-transcriptional inactivation of p14^{ARF} may contribute to tumorigenesis of retinoblastoma by unleashing *MDM2* to constitutively inhibit p53.

Acknowledgements

We thank Dr. Helen Dimaras for assistance with manuscript preparation and Clarelle Spencer for technical advice. This work was supported by the Ocular Oncology Program Fund of Princess Margaret Hospital, Toronto, Canada and NCI-NIH grant 5R01CA118830-04.

References

- Berger JH, Bardeesy N. Modeling INK4/ARF tumor suppression in the mouse. *Curr Mol Med* 2007;7:63–75. [PubMed: 17311533]
- Sherr CJ. Divorcing ARF and p53: an unsettled case. *Nat Rev Cancer* 2006;6:663–673. [PubMed: 16915296]
- Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. *Cell* 2006;127:265–275. [PubMed: 17055429]
- Gil J, Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. *Nat Rev Mol Cell Biol* 2006;7:667–677. [PubMed: 16921403]
- Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. *Cell* 1997;91:649–659. [PubMed: 9393858]
- Honda R, Yasuda H. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. *Embo J* 1999;18:22–27. [PubMed: 9878046]
- Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. *Nat Cell Biol* 1999;1:20–26. [PubMed: 10559859]
- Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. *Genes Dev* 1998;12:2424–2433. [PubMed: 9694806]
- de Stanchina E, McCurrach ME, Zindy F, Shieh SY, Ferbeyre G, Samuelson AV, Prives C, Roussel MF, Sherr CJ, Lowe SW. E1A signaling to p53 involves the p19(ARF) tumor suppressor. *Genes Dev* 1998;12:2434–2442. [PubMed: 9694807]
- Palmero I, Pantoja C, Serrano M. p19ARF links the tumour suppressor p53 to Ras. *Nature* 1998;395:125–126. [PubMed: 9744268]
- Lowe SW, Sherr CJ. Tumor suppression by Ink4a-Arf: progress and puzzles. *Curr Opin Genet Dev* 2003;13:77–83. [PubMed: 12573439]
- Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, Teunisse A, Lam S, Ramos Y, Mohan A, Johnson D, Wilson M, Rodriguez-Galindo C, Quarto M, Francoz S, Mendrysa SM, Guy RK, Marine JC, Jochemsen AG, Dyer MA. Inactivation of the p53 pathway in retinoblastoma. *Nature* 2006;444:61–66. [PubMed: 17080083]
- Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlov I, Lee HW, Cordon-Cardo C, DePinho RA. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. *Cell* 1998;92:713–723. [PubMed: 9529248]
- Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. *Cell* 1998;92:725–734. [PubMed: 9529249]

15. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. *Proc Natl Acad Sci U S A* 1998;95:8292–8297. [PubMed: 9653180]
16. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. *Embo J* 1998;17:5001–5014. [PubMed: 9724636]
17. Nork TM, Poulsen GL, Millicchia LL, Jantz RG, Nickells RW. p53 regulates apoptosis in human retinoblastoma. *Arch Ophthalmol* 1997;115:213–219. [PubMed: 9046256]
18. Kato MV, Shimizu T, Ishizaki K, Kaneko A, Yandell DW, Toguchida J, Sasaki MS. Loss of heterozygosity on chromosome 17 and mutation of the p53 gene in retinoblastoma. *Cancer Lett* 1996;106:75–82. [PubMed: 8827049]
19. Shvarts A, Steegenga WT, Riteco N, van Laar T, Dekker P, Bazuine M, van Ham RC, van der Houven van Oordt W, Hateboer G, van der Eb AJ, Jochemsen AG. MDMX: a novel p53-binding protein with some functional properties of MDM2. *Embo J* 1996;15:5349–5357. [PubMed: 8895579]
20. Reid TW, Albert DM, Rabson AS, Russell P, Craft J, Chu EW, Tralka TS, Wilcox JL. Characteristics of an established cell line of retinoblastoma. *J National Cancer Inst* 1974;53:1347–1360.
21. McFall RC, Sery TW, Makadon M. Characterization of a new continuous cell line derived from a human retinoblastoma. *Cancer Res* 1977;37:1003–1010. [PubMed: 844036]
22. Gallie BL, Campbell C, Devlin H, Duckett A, Squire JA. Developmental basis of retinal-specific induction of cancer by RB mutation. *Cancer Res* 1999;59:1731s–1735s. [PubMed: 10197588]
23. Corson TW, Gallie BL. One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma. *Genes Chromosomes Cancer* 2007;46:617–634. [PubMed: 17437278]
24. Komori H, Enomoto M, Nakamura M, Iwanaga R, Ohtani K. Distinct E2F-mediated transcriptional program regulates p14ARF gene expression. *Embo J* 2005;24:3724–3736. [PubMed: 16211008]
25. Robertson KD, Jones PA. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. *Mol Cell Biol* 1998;18:6457–6473. [PubMed: 9774662]
26. Tannapfel A, Busse C, Weinans L, Benicke M, Katalinic A, Geissler F, Hauss J, Wittekind C. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas. *Oncogene* 2001;20:7104–7109. [PubMed: 11704835]
27. Esteller M, Cordon-Cardo C, Corn PG, Meltzer SJ, Pohar KS, Watkins DN, Capella G, Peinado MA, Matias-Guiu X, Prat J, Baylin SB, Herman JG. p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. *Cancer Res* 2001;61:2816–2821. [PubMed: 11306450]
28. Watanabe T, Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H. Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas. *Acta Neuropathol (Berl)* 2001;101:185–189. [PubMed: 11307615]
29. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. *Nature* 1997;387:299–303. [PubMed: 9153396]
30. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. *FEBS Lett* 1997;420:25–27. [PubMed: 9450543]
31. Hopkins-Donaldson S, Belyanskaya LL, Simoes-Wust AP, Sigrist B, Kurtz S, Zangemeister-Wittke U, Stahel R. p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma. *Neoplasia* 2006;8:551–559. [PubMed: 16867217]
32. Shvarts A, Bazuine M, Dekker P, Ramos YF, Steegenga WT, Merckx G, van Ham RC, van der Houven van Oordt W, van der Eb AJ, Jochemsen AG. Isolation and identification of the human homolog of a new p53-binding protein, Mdmx. *Genomics* 1997;43:34–42. [PubMed: 9226370]
33. Marine JC, Dyer MA, Jochemsen AG. MDMX: from bench to bedside. *J Cell Sci* 2007;120:371–378. [PubMed: 17251377]
34. Toledo F, Wahl GM. MDM2 and MDM4: p53 regulators as targets in anticancer therapy. *Int J Biochem Cell Biol*. 2007
35. Dimaras H, Khetan V, Halliday W, Orlic M, Prigoda NL, Piovesan B, Marrano P, Corson TW, Eagle RC Jr, Squire JA, Gallie BL. Loss of RB1 induces non-proliferative retinoma: increasing genomic

instability correlates with progression to retinoblastoma. *Hum Mol Genet* 2008;17:1363–1372. [PubMed: 18211953]

36. Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. *Ophthalmol Clin North Am* 2005;18:41–53. [PubMed: 15763190]viii

Figure 1. Retinoblastoma highly expresses $p14^{ARF}$ mRNA but not protein

A. Quantitative RT-PCR analysis of $p14^{ARF}$ was performed on mRNA isolated from 6 normal human retinas, 14 retinoblastomas and 2 retinoblastoma cell lines (3 normal retinas (column 1–3), 4 primary retinoblastoma tumors (column 4–7) and 2 retinoblastoma cell lines (column 8 and 9) are shown). C33A, a human cervical cancer cell line, was used as positive control (column 10). Reactions were run in triplicate and calibrated to normal retina HR58 (column 1), using *TBP* as an endogenous control. Data shown are means (standard deviations were all too small (≤ 0.36) to be shown).

B. Immunohistochemistry of $p14^{ARF}$. Normal retina (panels a and b), retinoblastoma (RB) tumor RB2115 (panels c and d) and Hela cell (panels e and f), used as positive control, were stained with $p14^{ARF}$ specific Ab (Red) and DAPI (blue). Scale bars in panel a and b represent 40 μ m and in panel c–f 10 μ m.

C. Immunoblot analysis of p14^{ARF} was performed on normal retinas (lane 1–3), primary retinoblastoma tumors (lane 4–7) and retinoblastoma cell lines (lane 8 and 9) and C33A was used as positive control (lane 10). Upper panel p14^{ARF}, lower panel β -tubulin.

A

B

Figure 2. Retinoblastoma and normal retina express MDM4

A. Quantitative RT-PCR analysis of MDM4 expression in normal retinas (column 1–3), retinoblastoma cell lines (column 4 and 5) and primary retinoblastoma tumors (column 6–9). Data shown are mean $\pm$ standard deviation.

B. Immunoblot analysis of MDM4 in normal retinas (lane 1–3), retinoblastoma cell lines (lane 4 and 5) and primary retinoblastoma tumors (lane 6–8). Upper panel MDM4, lower panel β -tubulin.

Figure 3. MDM2 protein is expressed in all retinoblastomas and some normal retinas
Immunoblot analysis of MDM2 protein expression in normal retinas (lane 1–3), primary retinoblastoma tumors (lane 4–7 and 10) and retinoblastoma cell lines (lane and 9). HeLa cell was used as positive control (lane 11). Upper panel MDM2, lower panel β-tubulin.

Table 1

Samples used in this study

	Sample ID	Patient/Donor	Patient/Donor Gender	IIRC Group
Retinoblastoma	RB1904	2 months	Female	D
	RB1935	2.5 years	Male	D
	RB2115	1 year	Male	D
	RB2124	3 years	Female	Not available
	RB2132	4 years	Male	D
	RB2136	3 months	Male	D
	RB2146	1 year	Female	D
	RB2175	3 years	Female	Not available
	RB2180	1 year	Male	D
	RB2181	1 year	Female	D
	RB2238	1 year	Female	D
	RB2240	2 years	Male	D
	RB2244	4 months	Female	D
	RB2252	2 years	Female	Not available
	RB2253	4 months	Male	D
	RB2280	2.5 years	Female	E
	RB2284	3 years	Female	D
	RB2294	2 years	Male	D
	RB2527	3 years	Female	D
	RB2667	1 year	Male	D
Normal retina	RB2716	2 years	Male	E
	HFR18	14 months	Female	NA
	HFR20	2 years	Male	NA
	HR9	53 years	Female	NA
	HR47	13 years	Female	NA
	HR50	41 years	Female	NA
	HR58	12 days	Male	NA
	HR125	32 weeks	Male	NA
	HR130	15 years	Male	NA
	HR131	7 years	Male	NA
	HR141	4 days	Female	NA

NA: not applicable.

IIRC: International Intraocular Retinoblastoma Classification[36]